Venn Life Sciences Holdings PLC Director Declaration (9156C)

TIDMVENN

RNS Number : 9156C

Venn Life Sciences Holdings PLC

21 March 2014

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Change of Board

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that Paul Foulger, Finance Director, has given notice of his intention to resign from the Board with effect from 14 April 2014, to pursue a fulltime role within another public Company. It is the intention of the Board to appoint a qualified finance director as soon as a suitable candidate has been identified.

The Board takes this opportunity to wish Paul every success in his new role.

Enquiries:

 
 Venn Life Sciences Holdings 
  Plc. 
 Tony Richardson, Chief Executive       Tel: +353 154 99 341 
  Officer 
 Paul Foulger, Finance Director           Tel: 020 7933 8797 
 Orla McGuinness, Marketing           Tel: +33 (0)1 30 82 67 
  Manager                                                 07 
 
 Zeus Capital (Nominated Adviser 
  and Broker) 
 Ross Andrews/Andrew Jones                Tel: 0161 831 1512 
  (Corporate Finance) 
 John Goold/Dominic Wilson/Alex           Tel: 020 7533 7727 
  Davies (Institutional Sales) 
 
 Walbrook PR Ltd                       Tel: 020 7933 8787 or 
                                         venn@walbrookpr.com 
 Paul McManus                             Mob: 07980 541 893 
 Lianne Cawthorne                         Mob: 07584 391 303

Additional Information:

About Venn Life Sciences Limited: www.vennlifesciences.com

Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Germany, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe. The company's near term objectives are the expansion of its CRO business throughout Europe, whilst enhancing the portfolio of their innovative technologies division, InnoVenn, with ground breaking new products and services.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDNPGURPWUPCGWG

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024